Abstract

A metabolomic signature of acute mesenteric ischemia (AMI) and the determination thereof in a method for identifying a subject suffering or being at risk of suffering from AMI. Also, a kit that includes elements for determining the metabolomic signature of AMI and implementing the method for identifying a subject suffering or being at risk of suffering from AMI.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to tetracycline derivatives and their use as a medicament, in particular in treatment or prevention of a disease selected from the group comprising or consisting of: amyloidosis, pain, neurodegenerative diseases and neuroinflammatory diseases.

IPC Classes  ?

• C07C 235/82 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to vascular endothelial growth factor receptors (VEGFRs) inhibitors, in particular VEGFR-1 inhibitors, for use in promoting myelination and/or neuroprotection in a subject. The present invention also relates to compositions, pharmaceutical compositions, medicaments and kits of parts comprising VEGFR-1 inhibitors and their use for promoting myelination and/or neuroprotection in a subject.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids

Abstract

The present invention relates to the use of small organic molecules for treating or preventing myelin pathologies, such as, for example, multiple sclerosis and myelin pathologies associated with preterm birth.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/365 - Lactones
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil

Abstract

The use of recombinant AAV vectors expressing a molecule of interest in a method for treating diseases or conditions affecting the nervous system in a subject in need thereof, or in a method for increasing or inducing expression of the molecule of interest in the nervous system of a subject.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 38/46 - Hydrolases (3)
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

A screwing device (20) for use with a bone anchor (10) having a first axial passage and a force-receiving structure (13). The screwing device (20) having a second axial passage and a force-transfer structure, wherein an axis of the second axial passage is configured to coincide with an axis of the first axial passage when the screwing device (20) cooperates with the bone anchor (10) for receiving a rod of a marker (M) of a navigation system through the first and second axial passages of bone anchor (10) and the screwing device (20), wherein the screwing device (20) comprises a positioning arrangement (40) configured to maintain the marker (M) in a fixed position with respect to the screwing device (20) when the rod of the marker (M) is inserted in the second axial passage.

IPC Classes  ?

• A61B 17/86 - Pins or screws
• A61B 17/88 - Methods or means for implanting or extracting internal fixation devices
• A61M 39/02 - Access sites

Abstract

A method for predicting the return to functional autonomy in a subject suffering from an acute event, including the steps of i) determining neopterin level in a biological sample obtained from the subject; ii) comparing the level with its predetermined reference neopterin level and iii) predicting that the subject will have a long time to return to functional autonomy when the level of neopterin is higher than its predetermined reference neopterin level or predicting that the subject will have a short time to return to functional autonomy when the level of neopterin is lower than its predetermined reference neopterin level.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to a novel method for obtaining NK cells. The present invention further relates to a NK cell population, and to the use thereof for treating diseases, including cancer.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A system for automatic evaluation of cognition and consciousness of a subject, the system including a micro-controller, a digital-to-analog converter and at least one sensory stimulation element, wherein the system is configured to receive as input an information concerning a stimulation paradigm and to generate as output a sensory stimulation according to the stimulation paradigm and transmit at least one synchronization signal determined by the stimulation paradigm to a device for the acquisition of a physiological signal so as to synchronize the system for stimulation with the device for the acquisition of a physiological signal during an acquisition.

IPC Classes  ?

• A61B 5/383 - Somatosensory stimuli, e.g. electric stimulation
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to in vitro methods of distinguishing between ABMR and TCMR in an individual at risk of a kidney transplant rejection, or having any type of kidney transplant rejection, the method comprising the steps of :a) determining in a biopsy of said individual the expression level of at least two genes of a first set of genesand determining in said biopsy of said individual the expression level of at least two genes of a second set of genes b) comparing the expression levels of said at least 2 genes of the first set and said at least 2 genes of the second set with their expression level in a reference biopsy of a healthy individual with a kidney transplant.Figure 7.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a metabolomic signature of acute mesenteric ischemia (AMI) and the determination thereof in a method for identifying a subject suffering or being at risk of suffering from AMI. The present invention also relates to a kit comprising means for determining the metabolomic signature of AMI and implementing the method for identifying a subject suffering or being at risk of suffering from AMI.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a metabolomic signature of acute mesenteric ischemia (AMI) and the determination thereof in a method for identifying a subject suffering or being at risk of suffering from AMI. The present invention also relates to a kit comprising means for determining the metabolomic signature of AMI and implementing the method for identifying a subject suffering or being at risk of suffering from AMI.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

IPC Classes  ?

• A61K 39/112 - SalmonellaShigella
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 14/25 - Shigella (G)
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C07K 14/60 - Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• C07K 14/605 - Glucagons

Abstract

Shigella dysenteriaeShigella dysenteriae. It also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions comprising the same and their use in treatment, vaccination and diagnosis methods.

IPC Classes  ?

• A61K 39/112 - SalmonellaShigella
• C07K 14/25 - Shigella (G)
• A61P 35/00 - Antineoplastic agents

Abstract

A compound of formula (I): A compound of formula (I): A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A system to measure and monitor neurodegeneration of a subject, which includes: an acquisition module configured to acquire electroencephalographic signals with multiple EEG channels from a subject perceptually isolated; a calculation module configured to extract at least one EEG metric representative of neurodegeneration; and an evaluation module configured to evaluate the at least one EEG metric and extract a neurodegeneration index.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves

Abstract

Present application is related to a method for predicting the return to functional autonomy in a subject suffering from an acute event comprising the steps of i) determining neopterin level in a biological sample obtained from said subject; ii) comparing said level with its predetermined reference neopterin level and iii) predicting that the subject will have a long time to return to functional autonomy when the level of neopterin is higher than its predetermined reference neopterin level or predicting that the subject will have a short time to return to functional autonomy when the level of neopterin is lower than its predetermined reference neopterin level.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Present application is related to a method for predicting the return to functional autonomy in a subject suffering from an acute event comprising the steps of i) determining neopterin level in a biological sample obtained from said subject; ii) comparing said level with its predetermined reference neopterin level and iii) predicting that the subject will have a long time to return to functional autonomy when the level of neopterin is higher than its predetermined reference neopterin level or predicting that the subject will have a short time to return to functional autonomy when the level of neopterin is lower than its predetermined reference neopterin level.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A method for the generation of a consciousness indicator for a non-communicating subject, including generating a sensory stimulation involving at least one of the five senses, the sensory stimulation having multiple consecutive stimuli including at least a first stimulus and a second stimulus relating to the same sense and different from one another, measuring an electrocardiographic signal of the subject during the generation of the sensory stimulation, extracting at least one EKG feature from the electrocardiographic signal associated to cognitive processes and generating a consciousness indicator using the EKG features as input of a classifier.

IPC Classes  ?

• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61B 5/349 - Detecting specific parameters of the electrocardiograph cycle
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/372 - Analysis of electroencephalograms
• G06N 20/00 - Machine learning

Abstract

The present invention relates to a system (1) for automatic evaluation of cognition and consciousness of a subject, said system (1) comprising a micro-controller (11), a digital-to-analog converter (12) and at least one sensory stimulation element (13), wherein the system is configured to receive as input an information concerning a stimulation paradigm and to generate as output a sensory stimulation according to the stimulation paradigm and transmit at least one synchronization signal (10) determined by the stimulation paradigm to a device for the acquisition of a physiological signal (2) so as to synchronize the system for stimulation (1) with the device for the acquisition of a physiological signal (2) during an acquisition.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a system (1) for automatic evaluation of cognition and consciousness of a subject, said system (1) comprising a micro-controller (11), a digital-to-analog converter (12) and at least one sensory stimulation element (13), wherein the system is configured to receive as input an information concerning a stimulation paradigm and to generate as output a sensory stimulation according to the stimulation paradigm and transmit at least one synchronization signal (10) determined by the stimulation paradigm to a device for the acquisition of a physiological signal (2) so as to synchronize the system for stimulation (1) with the device for the acquisition of a physiological signal (2) during an acquisition.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0484 - Electroencephalography using evoked response

Abstract

A computer-implemented method for detecting pathological brain activity patterns from a scalp electroencephalographic signal, the method including the steps of obtaining (A) an electroencephalographic signal as a function of multiple channels and time; identifying (C), for each channel, the zero-crossings of the electroencephalographic signal over a fixed threshold; generating a zero-crossing representation of at least a segment of the obtained electroencephalographic signal with the identified zero-crossings; obtaining (D) a reference family of real functions of time and channels from a zero-crossing statistical analysis of zero-crossing representation of pre-recorded electroencephalographic signals; calculating (E) a matching score by comparing the zero-crossing representation of a segment of the electroencephalographic signal with at least one reference function from the reference family of functions; and computing the matching score as a function of time by sliding the at least one reference function from the reference family of functions over the electroencephalographic signal.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/372 - Analysis of electroencephalograms
• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]

Abstract

A); and generating an indicator of brain activity (Idx) of the subject when detecting the predefined pattern.

IPC Classes  ?

• G08B 21/04 - Alarms for ensuring the safety of persons responsive to non-activity, e.g. of elderly persons
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

The present invention relates to a method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods described herein are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

IPC Classes  ?

• A61K 39/112 - SalmonellaShigella
• C07K 14/25 - Shigella (G)

Abstract

The present invention relates to a compound of formula (I) wherein R1 is - a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is - a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. The present invention further relates to the compound of formula (I) as medicament.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C07D 487/04 - Ortho-condensed systems

Abstract

11436221366) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. The present invention further relates to the compound of formula (I) as medicament.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to methods and devices to consolidate memory and/or cognitive functions by monitoring brain rhythms and delivering a stimulus at an appropriate stage of sleep cycle.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61N 1/04 - Electrodes
• A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
• A61B 5/369 - Electroencephalography [EEG]

Abstract

A system to measure and monitor neurodegeneration of a subject, in particular preclinical Alzheimer's disease, comprises an acquisition module configured to acquire electroencephalographic signals with multiple EEC channels from a subject perceptually isolated (101); a calculation module configured to extract at least one EEC metric representative of neurodegeneration (102); and an evaluation module configured to evaluate the at least one EEC metric and extract a neurodegeneration index (103). The EEC metric is selected from the group of: weighted symbolic mutual information in at least one frequency band, power spectral density calculated in at least one frequency band, median spectral frequency, spectral entropy, algorithmic complexity.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61B 5/048 - Detecting the frequency distribution of signals

Abstract

The present invention relates to the treatment of drug-induced movement disorders, in particular of drug-induced dyskinesia, such as for example, levodopa-induced dyskinesia. More specifically, the present invention related to the use of a tetracycline compound, in particular doxycycline, minocycline and/or salts or derivatives thereof, for treating drug-induced movement disorders.

IPC Classes  ?

• A61K 31/65 - Tetracyclines
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a method for the generation of a consciousness indicator for a non-communicating subject, comprising generating a sensory stimulation involving at least one of the five senses (100), said sensory stimulation comprising multiple consecutive stimuli including at least a first stimulus and a second stimulus relating to the same sense and different from one another, measuring an electrocardiographic signal of the subject during the generation of the sensory stimulation (200), extracting at least one EKG feature from the electrocardiographic signal associated to cognitive processes (300) and generating a consciousness indicator using the EKG features as input of a classifier (400).

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Disclosed is a method for the generation of a consciousness indicator for a non-communicating subject, including the steps of generating an auditory stimulation, receiving an electrocardiographic signal of the subject obtained from a recording during the generation of the auditory stimulation, extracting at least one feature from the electrocardiographic signal and deducing a consciousness indicator from an analysis of the electrocardiographic feature.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
• A61B 5/38 - Acoustic or auditory stimuli
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/316 - Modalities, i.e. specific diagnostic methods
• A61B 5/349 - Detecting specific parameters of the electrocardiograph cycle

Abstract

an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

IPC Classes  ?

• A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis

Abstract

The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

IPC Classes  ?

• A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to biomarkers for typing or classifying allograft recipients as belonging to a transplant rejection group associated with antibody-mediated rejection (ABMR). The invention also provides for the treatment of typed allograft recipients suffering from antibody-mediated rejection by administration of an appropriate therapeutic agent.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

AAA); and generating an indicator of brain activity (Idx) of the subject when detecting the predefined pattern.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61B 5/0476 - Electroencephalography

Abstract

The present invention relates to probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in said subject. Preferably, said neurological disorder is an epileptic disease, disorder or condition.

IPC Classes  ?

• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention relates to probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in said subject. Preferably, said neurological disorder is an epileptic disease, disorder or condition.

IPC Classes  ?

• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

angelica dahurica, cnidium officinale, pogostemon cablin, mentha piperita, chrysanthellum americanum, camellia sinensis, zingiber officinale, citrus aurantium, saposhnikovia divaricata, eucalyptus globulus, xanthium strumariummagnolia biondiimagnolia biondii, and to the use of said composition for treating a benign disorder of short duration.

IPC Classes  ?

• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 36/232 - Angelica
• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/238 - Saposhnikovia
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/534 - Mentha (mint)
• A61K 36/575 - Magnolia
• A61K 36/61 - Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 11/02 - Nasal agents, e.g. decongestants

Abstract

The present invention relates to a computer-implemented method for detecting pathological brain activity patterns from a scalp electroencephaiographic signal, the method comprising the steps of obtaining (A) an electroencephaiographic signal as a function of multiple channels and time; identifying (C), for each channel, the zero- crossings of the electroencephaiographic signal over a fixed threshold; generating a zero-crossing representation of at least a segment of the obtained electroencephaiographic signal with the identified zero-crossings; obtaining (D) a reference family of real functions of time and channels from a zero-crossing statistical analysis of zero-crossing representation of pre-recorded electroencephaiographic signals; calculating (E) a matching score by comparing said zero-crossing representation of a segment of the electroencephaiographic signal with at least one reference function from the reference family of functions; and computing the matching score as a function of time by sliding the at least one reference function from the reference family of functions over the electroencephaiographic signal.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0476 - Electroencephalography

Abstract

The present invention relates to an in-ear stimulation system comprising a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject; wherein each of the first device and the second device comprises: − at least one in-ear active electrode (11,21) configured to receive a bio-signal and at least one in-ear reference electrode (12, 22) configured to receive a bio-signal; − at least one stimulation device (13, 23) configured for emitting at least one electrical or sensory stimulus; and − an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

The present invention relates to an agonist of the receptor of 1-[(2R,3R,4S,5R)-5-[[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid, preferably an agonist of two- pore channel 1 (TPC1) and/or two-pore channel 2 (TPC2), for the treatment and/or prevention of neurodegenerative disorders.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/10 - AntiepilepticsAnticonvulsants for petit-mal

Abstract

The present invention relates to a method for the differentiation of pluripotent stem cells into cardiomyocytes, comprising a step of activating at least one cardiac tissue-specific transcription factor.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/22 - Ribonucleases
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention relates to an in vitro method for the prognostic of a subject affected by a demyelinating disease comprising detecting and quantifying the level of at least one of CCL19, IL-15, ENA78 and/or TRAIL in a biological fluid from the subject. The invention also relates to the treatment of a subject affected by a demyelinating disease comprising the use of at least one modulator of CCL19, IL-15, ENA78 and/or TRAIL.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to methods and devices to consolidate memory and/or cognitive functions by monitoring brain rhythms and delivering a stimulus at an appropriate stage of sleep cycle.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
• A61N 1/04 - Electrodes
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to new synthetic compounds comprising a lipid diether to which a sugar group is grafted via a PEG spacer, and to now liposomes comprising at least one of said compounds. The invention particularly relates to new synthetic compounds of general formula (I) and to new liposomes comprising at least one of said compounds. The invention also relates to new liposomes for use as vectors and/or adjuvants, especially for use in vaccines.

IPC Classes  ?

• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

The present invention relates to the use of N-Methyl-D-aspartate (NMDA) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and/or impulsive behavior.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

The present invention relates to a non-invasive method for assessing the presence and/or severity of varices selected from gastric and esophageal varices in a liver disease patient, wherein said method comprises: (a) carrying out one or more non-invasive test(s) for assessing the severity of a hepatic lesion or disorder, wherein said non-invasive test(s) each result in a value, and (b) comparing the value(s) obtained at step (a) with cut-offs of said non-invasive test(s) for assessing the presence and/or severity of varices selected from gastric and esophageal varices.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification

Abstract

The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 14/55 - IL-2
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.

IPC Classes  ?

• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

The present invention relates to methods and devices to consolidate memory and/or cognitive functions by monitoring brain rhythms and delivering a stimulus at an appropriate stage of sleep cycle.

IPC Classes  ?

• A61B 5/0476 - Electroencephalography
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/04 - Electrodes

Abstract

A nine-hole pegboard test and a click test on the dominant hand are combined to obtain a score for the diagnosis of cerebellar impairment.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).

IPC Classes  ?

• C12N 15/867 - Retroviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61K 35/765 - ReovirusRotavirus
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/86 - Viral vectors
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/44 - Oxidoreductases (1)
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a method for diagnosing a cardiovascular event or disease in a subject by measuring sTREM-1 level in a sample.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for diagnosing a cardiovascular event or disease in a subject by measuring sTREM-1 level in a sample.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a composition comprising a depolarizing agent acting on a receptor expressed by the dopamine neurons of the substantia nigra, and a modulator of the nicotinic cholinergic pathway, wherein said receptor expressed by the dopamine neurons of the substantia nigra is an orexin receptor, a purinergic receptor or a neurokinin receptor; and to the use thereof for proving neuroprotection to a subject or for treating a disease, disorder or condition related to the dysfunction of the dopamine neurons of the substantia nigra in a subject.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a method for diagnosing an epileptic disease, disorder or condition in a subject, or determining a predisposition of a subject to an epileptic disease, disorder or condition or determining an increased risk of a subject of developing an epileptic disease, disorder or condition, wherein said method comprises determining the status of the DEPDC5 gene of the subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to a method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence of a gene that can restore energy failure. More particularly, the invention relates to a method for preventing or treating a cardiomyopathy associated with Friedreich ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a frataxin (FXN) encoding nucleic acid.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence of a gene that can restore energy failure. More particularly, the invention relates to a method for preventing or treating a cardiomyopathy associated with Friedreich ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a frataxin (FXN) encoding nucleic acid.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, or determining a predisposition of a subject to a neurodegenerative disease or determining an increased risk of a subject of developing a neurodegenerative disease, wherein said method comprises determining the protein level of C90RF72 in a body fluid of the subject, and comparing said protein level to a reference value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a composition comprising an inhibitor of the COMT enzyme for use in the treatment of a Neurodegenerative Disease with Parkinsonian Syndromes in a subject having a COMTH allele, wherein said composition does not comprise L-Dopa.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
• A61K 31/11 - Aldehydes
• A61K 31/12 - Ketones
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a method for obtaining a value of a score for diagnosing the stage of evolution of human hepatic fibrosis, in which: one or more respective pieces of data are obtained for a patient, said data relating to at least one of the markers selected from the group consisting of mean corpuscular volume and liver elasticity; and a value is calculated by combining said data with data of other markers.

IPC Classes  ?

• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• G06F 19/12 - for modelling or simulation in systems biology, e.g. probabilistic or dynamic models, gene-regulatory networks, protein interaction networks or metabolic networks
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons